Indianapolis researchers are using a Small Business Innovation Research grant to develop technology which could alleviate negative side effects during stem cell transplants for cancer patients.
General BioTechnology will use a $350,000 grant from the state to further develop and test its Advanced CryoTechnology Cell Washing Device. The Indiana grant accompanies federal funding of more than $1 million to develop the device for clinical use. The company plans to begin a pilot safety study of the technology in the first quarter of 2010 with Indiana University before a larger clinical trial later in the year continuing with the Fred Hutchison Cancer Research Center in Seattle, Wash., and Indiana University.
"We must continue to support companies like General BioTechnology that are leading the charge to increase the safety and comfort of medical procedures," said Mitch Roob, Secretary of Commerce and chief executive officer of the Indiana Economic Development Corporation. "We know that high-technology companies like this will create the jobs of tomorrow, but more importantly, they have the potential to improve the quality of life for people across the world."
General BioTechnology's device, which is similar in size to a microwave oven, pumps bone marrow stem cells through a specially designed tube. The fiber filled tube gradually filters the Dimethyl Sulfoxide preservative from the bone marrow transplant while still maintaining the cell's efficacy. DMSO is a commonly used preservative which increases the shelf life of cells, but can cause complications with patients when it is injected into their system.
"There has been a demand for this technology as long as frozen bone marrow transplants have been used to treat patients. This project originated through our company's mission of listening to physicians and specifically developing technologies to meet critical needs," said Erik J. Woods, Ph.D., president and chief executive officer of General BioTechnology. "Over 30,000 people a year in this country receive this type of procedure, our hope is that our system will help yield better outcomes with fewer complications."
Beyond this initial trial for bone marrow, ongoing research involves using the cell washing device to more effectively remove glycerol from standard frozen blood, making it more accessible to a wider pool of patients. According to the National Heart, Lung and Blood Institute, there are currently more than 5 million blood transfusions performed in this country per year, mostly using fresh blood which spoils in about one month using standard storage techniques. Woods estimates that General BioTechnology's device could allow medical personnel to administer frozen blood in as little as 30 minutes. It's a process he says normally takes up to three or four hours.
Woods anticipates commercializing the device to the bone marrow stem cell transplant markets in late 2010 before fully launching the product to blood centers throughout North America in 2011. Indianapolis-based Medivative Technologies will manufacture the cell washing technology.
"The Medivative team is pleased to assist another Indiana company in the development and manufacture of an innovative medical device," said Bryan Bowman, Medivative's president. "General BioTechnology's Cell Washing Device will improve the quality of life for people recovering from cancer."
Founded in 1997 General BioTechnology has, to date, focused on umbilical cord blood stem cell research and sperm banking. Research on the cell washing technology began in 2000. The company has also launched the first cell manufacturing facility of its kind in the state, manufacturing cell therapy products for clinical trials to be performed at Indiana University. The company currently operates out of the Harlan Biotechnology Center near the IUPUI campus.
General BioTechnology is one of more than 120 companies that the Indiana Economic Development Corporation has assisted in securing funding from the federal government's Small Business Innovation Research and Small Business Technology Transfer program. The SBIR/STTR is an effort by 11 federal agencies to accelerate the development of high-tech products for use by the government and consumers around the globe. The agency's efforts to boost federal funding for Indiana business have resulted in a more than 62 percent increase in federal dollars to Indiana entrepreneurial businesses.
About General BioTechnology
General BioTechnology LLC (GBT) was founded in 1997 by former Indiana University School of Medicine researchers. The company was initially based on novel technologies including methods and devices specifically related to giving biological cells and tissues shelf life. General BioTechnology has been awarded several federal grants to improve the cryopreservation and banking methods of diverse cell and tissue types including human pancreatic islets of Langerhans, blood platelets, umbilical cord blood, peripheral blood stem cells and spermatozoa. For more information visit www.gnrlbiotech.com
About IEDC
Created by Governor Mitch Daniels in 2005 to replace the former Department of Commerce, the Indiana Economic Development Corporation is governed by a 12-member board chaired by Governor Daniels. Indiana Secretary of Commerce Mitch Roob serves as the chief executive officer of the IEDC. For more information about IEDC, visit www.iedc.in.gov.
There are no comments
Please login to post comments